B Group Inc. Makes New $1.16 Million Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

B Group Inc. acquired a new stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 50,000 shares of the company's stock, valued at approximately $1,164,000. Spyre Therapeutics makes up approximately 0.7% of B Group Inc.'s portfolio, making the stock its 12th largest position. B Group Inc. owned 0.10% of Spyre Therapeutics as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Barclays PLC increased its position in Spyre Therapeutics by 64.7% during the 3rd quarter. Barclays PLC now owns 105,467 shares of the company's stock valued at $3,101,000 after purchasing an additional 41,424 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Spyre Therapeutics in the 4th quarter worth $290,000. Victory Capital Management Inc. bought a new stake in Spyre Therapeutics during the fourth quarter valued at approximately $6,241,000. Jane Street Group LLC lifted its position in Spyre Therapeutics by 78.7% during the third quarter. Jane Street Group LLC now owns 20,641 shares of the company's stock valued at $607,000 after purchasing an additional 9,090 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Spyre Therapeutics by 16.4% in the 3rd quarter. Geode Capital Management LLC now owns 891,048 shares of the company's stock worth $26,211,000 after acquiring an additional 125,214 shares in the last quarter. Institutional investors own 80.39% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on the stock. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 18th. Leerink Partners initiated coverage on Spyre Therapeutics in a research report on Tuesday, April 8th. They set an "outperform" rating and a $45.00 price objective on the stock. Wolfe Research initiated coverage on Spyre Therapeutics in a research report on Tuesday, March 18th. They set an "outperform" rating and a $27.00 target price on the stock. Leerink Partnrs upgraded Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, April 8th. Finally, Wedbush reaffirmed an "outperform" rating and set a $65.00 price objective on shares of Spyre Therapeutics in a research note on Monday, January 13th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Spyre Therapeutics currently has an average rating of "Buy" and a consensus price target of $49.57.

Spyre Therapeutics Price Performance

Shares of SYRE traded up $0.71 during mid-day trading on Thursday, reaching $14.93. The stock had a trading volume of 1,004,309 shares, compared to its average volume of 598,181. Spyre Therapeutics, Inc. has a 52-week low of $10.91 and a 52-week high of $40.49. The firm has a market cap of $899.92 million, a price-to-earnings ratio of -2.00 and a beta of 3.05. The business's fifty day moving average is $16.73 and its 200 day moving average is $23.39.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.08. As a group, sell-side analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).